Strs Ohio grew its position in NantKwest, Inc. (NASDAQ:NK) by 21.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,500 shares of the biotechnology company’s stock after purchasing an additional 1,300 shares during the quarter. Strs Ohio’s holdings in NantKwest were worth $52,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in NK. Bank of Montreal Can bought a new position in shares of NantKwest in the second quarter valued at approximately $32,000. FNY Investment Advisers LLC acquired a new stake in shares of NantKwest in the third quarter worth $41,000. Point72 Hong Kong Ltd acquired a new stake in shares of NantKwest in the third quarter worth $48,000. BNP Paribas Arbitrage SA grew its stake in shares of NantKwest by 522.8% in the third quarter. BNP Paribas Arbitrage SA now owns 7,231 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 6,070 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new stake in shares of NantKwest in the third quarter worth $51,000. 9.22% of the stock is currently owned by institutional investors.
NK opened at $13.33 on Friday. NantKwest, Inc. has a fifty-two week low of $2.52 and a fifty-two week high of $19.37. The firm’s fifty day moving average price is $10.83 and its two-hundred day moving average price is $9.77. The company has a market capitalization of $1.45 billion, a P/E ratio of -18.77 and a beta of 2.52.
Several equities research analysts have recently issued reports on NK shares. BidaskClub downgraded shares of NantKwest from a “hold” rating to a “sell” rating in a research note on Friday, October 23rd. Zacks Investment Research upgraded shares of NantKwest from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 14th.
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Further Reading: How does a margin account work?
Receive News & Ratings for NantKwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest and related companies with MarketBeat.com's FREE daily email newsletter.